Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 17, 2009 Brian Orelli	Investors Heart Medtronic The leaner company is more lovable.
The Motley Fool February 17, 2005 Stephen D. Simpson	Is Medtronic's Heartbeat Slowing? Will gradually decelerating growth lead to a multiple contraction on the medical device maker's stock?
The Motley Fool August 20, 2008 Brian Orelli	Medtronic Muddles Through The medical device maker manages double-digit growth in a tough market.
The Motley Fool February 24, 2010 Brian Orelli	Medtronic Needs to Regrow a Spine Everything else looks fairly good, but the problem I see involves the slight decline in Medtronic's second-largest segment, spinal products.
The Motley Fool November 18, 2004 W.D. Crotty	Medtronic Down, Not Out Internal defibrillator maker's earnings growth rate is slowing down, but its future looks healthy.
The Motley Fool August 25, 2009 Brian Orelli	Medtronic Takes the Road Less Traveled It looks like this medical devices company is healthy again.
The Motley Fool May 26, 2005 Stephen D. Simpson	A Second Opinion on Medtronic Medtronic is a growth stalwart, but does valuation properly account for the challenges?
The Motley Fool January 6, 2005 Stephen D. Simpson	Can Medtronic Still Quicken the Pulse? While increased competition looms for the medical device maker, a shareholder update looks to the past.
The Motley Fool May 21, 2008 Brian Orelli	Medtronic's Endeavors Look Good The medical device maker's new drug-eluting stent helps push up revenue.
The Motley Fool February 12, 2004 Jeff Hwang	Rockin' Medtronic The world's premier medical device maker keeps on growing.
The Motley Fool April 20, 2005 Stephen D. Simpson	St. Jude's Healthy Heartbeat Medical device maker St. Jude continues to be boosted by ICD market share gains, and new businesses are coming on line, as well.
The Motley Fool November 18, 2008 Brian Orelli	No Buffer for Medtronic Even though sales grew for the quarter, investors weren't happy.
The Motley Fool May 25, 2010 Brian Orelli	Medtronic Gets Tossed Out With the Bathwater A bad day to report good news.
The Motley Fool January 25, 2006 Stephen D. Simpson	Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note.
The Motley Fool October 8, 2007 Billy Fisher	Vital Signs at Medtronic The FDA raises question about Medtronic's Endeavor stent. Investors, remember that the company also has a well-diversified product portfolio to protect itself against any unforeseen pitfalls ahead.
The Motley Fool February 22, 2006 Stephen D. Simpson	Medtronic's Minor Miss Sluggish sales in several market categories might spook investors.
The Motley Fool November 24, 2009 Brian Orelli	52-Week Highs! What's Going On? Even with its recent leap, this stock may belong in your portfolio. Medtronic raised earnings guidance today after a fairly strong quarter, and the stock is hitting new 52-week highs.
The Motley Fool August 22, 2007 Ryan Fuhrmann	Upbeat About Medtronic The future looks bright at medical-device firm Medtronic, and the stock price is reasonable. First quarter sales grew, as overseas revenue improved an impressive 16%.
The Motley Fool October 16, 2007 Billy Fisher	A Heartbreaker at Medtronic The medical device maker halts distribution of certain defibrillator wires. Shares of Medtronic are now very close to the stock's 52-week low.
The Motley Fool February 20, 2008 Brian Orelli	Medtronic Looks Ahead After a rough second half of last year, Medtronic is leaving its problems behind, and optimistically focusing on the future.
The Motley Fool August 18, 2008 Brian Orelli	Foolish Forecast: Taking Medtronic to Heart In advance of earnings analysts expect Medtronic, with another medical device approval, to boost revenues 17%.
The Motley Fool May 24, 2006 Stephen D. Simpson	Measuring Up Medtronic Everyone loves the med-tech firm. That makes it a dangerous investment.
The Motley Fool January 26, 2005 Stephen D. Simpson	St. Jude Is No Lost Cause The No. 3 cardiology company posts solid growth because of continuing implantable cardioverter defibrillator (ICD) market share gains.
The Motley Fool May 24, 2007 Ryan Fuhrmann	Chronic Healthiness at Medtronic The med-tech firm isn't growing as fast as it once was, but its fourth-quarter earnings report still managed to beat Wall Street's expectations.
The Motley Fool April 19, 2007 Billy Fisher	A Saintly Quarter Shares of St. Jude Medical rise after the company announces a big quarter.
The Motley Fool November 22, 2011 Brian Orelli	A Little Diversity Goes a Long Way Especially in this economy.
The Motley Fool August 23, 2006 Stephen D. Simpson	Is Medtronic Sweeping the Deck? Nothing's changing at a deep fundamental level in health care that would impede the growth of this giant med-tech corporation. However, investors need to proceed with caution.
The Motley Fool May 25, 2005 W.D. Crotty	Medtronic's Sneak Preview The medical technology company, a 26-bagger, turns in another strong quarter and fiscal year, then offers quite an outlook.
The Motley Fool July 18, 2008 Brian Orelli	St. Jude Is a Fighter The medical device maker continues to kick the competition while it's down.
The Motley Fool April 19, 2006 Stephen D. Simpson	St. Jude Lives and Learns Though dynamics in the ICD market caught it by surprise, this is still a quality med-tech company. Investors, take note.
The Motley Fool November 15, 2007 Rich Smith	Foolish Forecast: Mulling Medtronic In advance of earnings reports, analysts expect sales from the medical-equipment maker to remain flat and profit to fall slightly.
The Motley Fool December 31, 2007 Brian Orelli	Boston Scientific Restarts Its Heart Boston Scientific receives European approval for its defibrillator, giving the company a revenue boost even if the U.S. approval is delayed.
The Motley Fool August 4, 2006 Stephen D. Simpson	Medtronic's Shock to the System Its guidance cuts rattled the med-tech industry, but long-term trends remain positive. While the going may be tougher now in the ICD space, it's still an attractive long-term opportunity, and investors may want to start looking around for bargains.
The Motley Fool February 26, 2008 Brian Orelli	Quick Take: Boston Scientific Gets Approved -- Thrice The medical device maker is granted three FDA approvals in one day.
The Motley Fool August 24, 2011 Brian Orelli	Growth, but Not Great Growth Medtronic's growth comes with lower margins.
The Motley Fool August 31, 2011 Harsh Chauhan	Medtronic Looks Set for Takeoff Medtronic shares jump after flat quarterly growth as it looks toward global expansion.
The Motley Fool November 21, 2006 Ryan Fuhrmann	Shocking Results at Medtronic Favorable earnings boost shares of this medical equipment maker -- but are they too high already?
The Motley Fool July 19, 2006 Stephen D. Simpson	Taking St. Jude's Pulse The ICD market is a long-term opportunity, but not a panacea. St. Jude investors should remember that this is a rough neighborhood -- product liability, FDA bureaucracy, and huge, tough competitors live here, too.
The Motley Fool October 20, 2009 Robert Steyer	The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it.
The Motley Fool November 21, 2007 Rich Smith	Medtronic Motors Ahead Shares of the medical equipment maker soared yesterday and continue to buck the downtrend on Wall Street, in the wake of a fiscal Q2 2008 earnings report that exceeded expectations for both sales and profits.
The Motley Fool February 5, 2008 Brian Orelli	Boston Scientific Gets Charged Walloped by charges, Boston Scientific posts a loss for the quarter.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Busy Day for St. Jude In addition to announcing a major acquisition, St. Jude also reported very solid financial results for the third quarter. Analysts keep raising the bar, and the medical equipment company continues to surpass it.
The Motley Fool January 29, 2009 Brian Orelli	No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed.
The Motley Fool July 20, 2005 Stephen D. Simpson	Hey, Jude! Party Hearty St. Jude's ICD (implantable cardioverter defibrillator) business is on fire and fueling strong profit growth for this medical device maker. Whether your cut-off makes St. Jude a mid-cap or a large-cap, this company is certainly growing -- and the stock's valuation reflects that.
The Motley Fool February 12, 2010 Brian Orelli	Too Bad It's Not in the "Restructuring" Business Shares of Boston Scientific slipped nearly 10% yesterday, after the company released earnings and guidance for this year.
The Motley Fool April 5, 2006 Stephen D. Simpson	St. Jude's Racing Heartbeat Slows Even though the stock got far too expensive, this is still a good company and could still be a viable target for certain large health-care companies that may be in an acquisition frame of mind.
The Motley Fool August 24, 2010 Brian Orelli	Disaster in Medical-Device Land Industry bellwether Medtronic is forecasting a nasty storm.
The Motley Fool May 24, 2006 S.J. Caplan	Goodbye, Guidant Publicity woes drive Boston Scientific to ditch the Guidant name. In the meantime, Boston Scientific wants to capitalize on its entry into the ICD market, an area experiencing double-digit sales growth. Investors, take note.
The Motley Fool December 29, 2011 Harsh Chauhan	Why Medtronic Is On Course for a Happy New Year Right moves make Medtronic a good investment now.
The Motley Fool December 5, 2005 Stephen D. Simpson	Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note.